^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yonsa (abiraterone acetate)

    i
    Other names: AAFP, abiraterone acetate fine particle, submicron abiraterone acetate
    Associations

    News

    Trials
    Company:
    Churchill Pharma, Sun Pharma
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial (clinicaltrials.gov)
    P2, N=202, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    abiraterone acetate • Eligard (leuprolide acetate) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
    4d
    Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. (clinicaltrials.gov)
    P2, N=192, Recruiting, Sun Pharmaceutical Industries Limited | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jun 2025 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    enzalutamide • apalutamide • Yonsa (abiraterone acetate)
    1m
    OMAHA-003: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1310, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2028 --> Feb 2030
    Trial completion date
    |
    enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    3ms
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Terminated, M.D. Anderson Cancer Center | Trial completion date: Apr 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2027 --> Mar 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)
    7ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1314, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open
    |
    enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    8ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1314, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Dec 2030 --> May 2028
    Trial primary completion date
    |
    enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    9ms
    Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. (clinicaltrials.gov)
    P1, N=50, Terminated, University of Chicago | Trial completion date: Nov 2025 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Nov 2024; Closed by PI due to not meeting primary endpoint
    Trial completion date • Trial termination • Trial primary completion date
    |
    abiraterone acetate • Yonsa (abiraterone acetate)
    9ms
    OMAHA1: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1310, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open
    |
    enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    10ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1500, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    12ms
    OMAHA1: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    1year
    Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer (clinicaltrials.gov)
    P2, N=110, Recruiting, Mayo Clinic | N=57 --> 110
    Enrollment change
    |
    abiraterone acetate • Yonsa (abiraterone acetate)
    1year
    A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces (clinicaltrials.gov)
    P=N/A, N=2313, Completed, Pfizer | N=1000 --> 2313
    Enrollment change
    |
    enzalutamide • abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)